SCHEMBL3924364

SCHEMBL3924364

O=c1c(Br)cncn1Cc1ccccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
ALDH1A1 P00352 4/20 0.47
THRB P10828 1/20 0.45
MAPT P10636 2/20 0.44
TP53 P04637 3/20 0.43
POLB P06746 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PKM P14618 1/20 0.43
PKLR P30613 1/20 0.43
GRM2 Q14416 1/20 0.41
PLA2G1B P04054 1/20 0.41
ATG4B Q9Y4P1 1/20 0.41
HPGD P15428 2/20 0.40
TSHR P16473 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HSD17B10 Q99714 2/20 0.40
ROCK2 O75116 1/20 0.40
CNR2 P34972 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3920702 0.82 MEN1 (0.51) LMNAALDH1A1POLBPLA2G1BATG4B
SCHEMBL3913519 0.82 SMN1; SMN2 (0.55) LMNAALDH1A1THRBMAPTTP53
SCHEMBL3915712 0.81 GRM2 (0.44) MAPTTP53GRM2TSHRSMN1; SMN2
SCHEMBL3912721 0.78 CYP11B1 (0.54) LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL3914923 0.76 CYP11B1 (0.54) LMNAALDH1A1THRBMAPTL3MBTL1
SCHEMBL3927346 0.75 ALDH1A1 (0.47) LMNAALDH1A1MAPTTP53L3MBTL1
SCHEMBL3913554 0.73 LMNA (0.42) LMNAALDH1A1THRBMAPTTP53
SCHEMBL6928773 0.73 CYP11B1 (0.48) LMNAALDH1A1MAPTPOLBL3MBTL1
SCHEMBL3921716 0.72 CHRM1 (0.34) LMNAPKMTSHR
SCHEMBL3916349 0.72 PDPK1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE GAUDINO JOHN 2011-03-03 US disclosed
EP-2032538-A2 QUINOLINE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2009-03-11 EP disclosed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE TK1, ABL1, ROR1 LMNA 1139/4885ALDH1A1 1526/4885THRB 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.